Diagnostics specialists win the US device approval race
The speediest device developer is Roche, but a look at companies’ strategies shows the perils of relying on bought-in tech.
Bavarian’s chance to draw a line under oncology
The Danish group seizes an opportunity to focus on what it does best, but its ill-fated flirtation with oncology continues.
Neon and Neurotrope await signs of proof of concept
Neon Therapeutics is due to unveil the first rigorous test of its neoantigen approach to fighting tumours, while Neurotrope makes a brave bid in Alzheimer's.
More Sanofi dengue setbacks could benefit Takeda
Sanofi might only get the US go-ahead for its dengue vaccine Dengvaxia in a narrow population, leaving the door open for its rival Takeda.
Upcoming events – pivotal data loom for Novavax and Mallinckrodt
Novavax awaits phase III data with its respiratory syncytial virus vaccine ResVax, while Mallinckrodt hopes to bounce back with its next big pipeline hope, CPP-1X plus…
Eli Lilly backs away from Bace but not from novel Alzheimer’s targets
The amyloid beta hypothesis persists in spite of repeated failure as biopharma refines targets and mechanisms of action.
Upcoming events – Takeda awaits dengue data and Regenxbio needs more heartening results
Takeda will soon report phase III results with its dengue fever vaccine, while Regenxbio needs an improvement with its cholesterol-lowering gene therapy candidate,…
Oncolytics prepares to tap US investors
The tiny biotech has wasted no time in jumping on the oncolytic virus deal-making bandwagon, but dilution is nevertheless still likely.
Biosimilars the beneficiary of new Medicare step therapy rule
Medicare Advantage plans have been cleared to seek cheaper alternatives for biologicals beginning next year.
